Literature DB >> 2177782

Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen.

E H Wasmuth1, W J Miller.   

Abstract

The development of an ELISA of increased sensitivity has permitted a more critical evaluation of human humoral immune responses to the live attenuated varicella (Oka/Merck) vaccine. For use as a solid-phase antigen, the glycoprotein (gp) antigens are prepared by lectin-affinity chromatography from lysates of VZV-infected MRC-5 cells. The lot-to-lot variation in VZV gp content is controlled by standardization of antigen against a panel of human serum providing antigen-coated plates of consistent quality. The increased sensitivity of the gpELISA over the VAR ELISA is reflected in the greater seroconversion rate and prepositive rate specificity. These determinations have been shown to be specific for anti-VZV by absorption experiments using purified VZV gp antigens.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2177782     DOI: 10.1002/jmv.1890320310

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  19 in total

1.  A double-blind, randomized, multicenter, controlled study to evaluate the immunogenicity, safety, and tolerability of varicella vaccine (VARIVAX™) passage extension 34 (PE34) process administered concomitantly with measles, mumps, and rubella vaccine (M-M-R™ II).

Authors:  Peter E Silas; Edward N Zissman; Julie Gardner; Shanjun Helian; Andrew W Lee; Heather L Platt
Journal:  Hum Vaccin Immunother       Date:  2020-05-19       Impact factor: 3.452

2.  Serological detection of varicella-zoster virus-specific immunoglobulin G by an enzyme-linked immunosorbent assay using glycoprotein antigen.

Authors:  A Sauerbrei; P Wutzler
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

Review 3.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

4.  Reactivity of varicella-zoster virus subunit antigens in enzyme-linked immunosorbent assay to sera from varicella, zoster, and herpes simplex virus infections.

Authors:  M Takayama
Journal:  Med Microbiol Immunol       Date:  1994-02       Impact factor: 3.402

5.  A systematic approach for the identification of novel, serologically reactive recombinant Varicella-Zoster Virus (VZV) antigens.

Authors:  Maria G Vizoso Pinto; Klaus-Ingmar Pfrepper; Tobias Janke; Christina Noelting; Michaela Sander; Angelika Lueking; Juergen Haas; Hans Nitschko; Gundula Jaeger; Armin Baiker
Journal:  Virol J       Date:  2010-07-20       Impact factor: 4.099

6.  Detection of antibodies to varicella-zoster virus in recipients of the varicella vaccine by using a luciferase immunoprecipitation system assay.

Authors:  Jeffrey I Cohen; Mir A Ali; Ahmad Bayat; Sharon P Steinberg; Hosun Park; Anne A Gershon; Peter D Burbelo
Journal:  Clin Vaccine Immunol       Date:  2014-07-02

7.  A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax.

Authors:  Larry I Gilderman; James F Lawless; Thomas M Nolen; Tina Sterling; Ruth Z Rutledge; Doreen A Fernsler; Neal Azrolan; Santosh C Sutradhar; William W Wang; Ivan S F Chan; Katia Schlienger; Florian Schödel; Jeffrey L Silber
Journal:  Clin Vaccine Immunol       Date:  2007-12-12

8.  A double blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps rubella, and varicella vaccine (MMRV) manufactured using an alternative process.

Authors:  Gary S Marshall; Shelly D Senders; Julie Shepard; Jerry D Twiggs; Julie Gardner; Darcy Hille; Jonathan Hartzel; Rowan Valenzuela; Jon E Stek; Frans A Helmond
Journal:  Hum Vaccin Immunother       Date:  2016-05-05       Impact factor: 3.452

9.  Performance of a time-resolved fluorescence immunoassay for measuring varicella-zoster virus immunoglobulin G levels in adults and comparison with commercial enzyme immunoassays and Merck glycoprotein enzyme immunoassay.

Authors:  P A C Maple; J Gray; J Breuer; G Kafatos; S Parker; D Brown
Journal:  Clin Vaccine Immunol       Date:  2006-02

Review 10.  Recognition and treatment of shingles.

Authors:  A F Nikkels; G E Piérard
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.